Progress in cancer gene therapy

David T. Curiel, Winald R. Gerritsen, Mark R L Krul

Research output: Contribution to journalArticle

Abstract

The 'First International Symposium on Genetic Anticancer Agents,' which took place in Amsterdam on March 8-9, 2000, served as a forum to review the results of preclinical and clinical gene therapy studies for cancer endeavored to date. Despite the fact that gene therapy was initially conceptualized as an approach for inherited genetic disease, it is currently finding its widest employ for treating neoplastic disorders. In this regard, more than 70% of patients treated to date in human clinical gene therapy protocols have been in the context of anticancer regimens.1 Of note, the application of gene therapy for cancer has proceeded from the same rational basis as was originally conceptualized for inherited genetic disorders. Specifically, the molecular basis of these disorders is increasingly being understood, therapeutic genes are available, and alternative therapies are often lacking. Most recently, the field of gene therapy has enjoyed the realization of the first incontrovertible evidence of clinical benefit, for hemophilia and cardiovascular disease, in its first 15 years of human application.2 This recent recognition of the potential power of gene therapy, and the current lack of realizing such ends for neoplastic disease, has led to a reassessment of the field. Such a critical analysis is a necessary step in defining the means to progress the technology toward achieving the potential benefits of gene therapy for cancer.

Original languageEnglish (US)
Pages (from-to)1197-1199
Number of pages3
JournalCancer Gene Therapy
Volume7
Issue number8
StatePublished - 2000
Externally publishedYes

Fingerprint

Neoplasm Genes
Genetic Therapy
Inborn Genetic Diseases
Neoplasms
Hemophilia A
Complementary Therapies
Antineoplastic Agents
Cardiovascular Diseases
Technology

Keywords

  • Clinical trials
  • Gene therapy
  • Preclinical research
  • Replication
  • Targeting
  • Vectors

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Curiel, D. T., Gerritsen, W. R., & Krul, M. R. L. (2000). Progress in cancer gene therapy. Cancer Gene Therapy, 7(8), 1197-1199.

Progress in cancer gene therapy. / Curiel, David T.; Gerritsen, Winald R.; Krul, Mark R L.

In: Cancer Gene Therapy, Vol. 7, No. 8, 2000, p. 1197-1199.

Research output: Contribution to journalArticle

Curiel, DT, Gerritsen, WR & Krul, MRL 2000, 'Progress in cancer gene therapy', Cancer Gene Therapy, vol. 7, no. 8, pp. 1197-1199.
Curiel DT, Gerritsen WR, Krul MRL. Progress in cancer gene therapy. Cancer Gene Therapy. 2000;7(8):1197-1199.
Curiel, David T. ; Gerritsen, Winald R. ; Krul, Mark R L. / Progress in cancer gene therapy. In: Cancer Gene Therapy. 2000 ; Vol. 7, No. 8. pp. 1197-1199.
@article{3ec49792c92b4e0390664ee297687ea8,
title = "Progress in cancer gene therapy",
abstract = "The 'First International Symposium on Genetic Anticancer Agents,' which took place in Amsterdam on March 8-9, 2000, served as a forum to review the results of preclinical and clinical gene therapy studies for cancer endeavored to date. Despite the fact that gene therapy was initially conceptualized as an approach for inherited genetic disease, it is currently finding its widest employ for treating neoplastic disorders. In this regard, more than 70{\%} of patients treated to date in human clinical gene therapy protocols have been in the context of anticancer regimens.1 Of note, the application of gene therapy for cancer has proceeded from the same rational basis as was originally conceptualized for inherited genetic disorders. Specifically, the molecular basis of these disorders is increasingly being understood, therapeutic genes are available, and alternative therapies are often lacking. Most recently, the field of gene therapy has enjoyed the realization of the first incontrovertible evidence of clinical benefit, for hemophilia and cardiovascular disease, in its first 15 years of human application.2 This recent recognition of the potential power of gene therapy, and the current lack of realizing such ends for neoplastic disease, has led to a reassessment of the field. Such a critical analysis is a necessary step in defining the means to progress the technology toward achieving the potential benefits of gene therapy for cancer.",
keywords = "Clinical trials, Gene therapy, Preclinical research, Replication, Targeting, Vectors",
author = "Curiel, {David T.} and Gerritsen, {Winald R.} and Krul, {Mark R L}",
year = "2000",
language = "English (US)",
volume = "7",
pages = "1197--1199",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Progress in cancer gene therapy

AU - Curiel, David T.

AU - Gerritsen, Winald R.

AU - Krul, Mark R L

PY - 2000

Y1 - 2000

N2 - The 'First International Symposium on Genetic Anticancer Agents,' which took place in Amsterdam on March 8-9, 2000, served as a forum to review the results of preclinical and clinical gene therapy studies for cancer endeavored to date. Despite the fact that gene therapy was initially conceptualized as an approach for inherited genetic disease, it is currently finding its widest employ for treating neoplastic disorders. In this regard, more than 70% of patients treated to date in human clinical gene therapy protocols have been in the context of anticancer regimens.1 Of note, the application of gene therapy for cancer has proceeded from the same rational basis as was originally conceptualized for inherited genetic disorders. Specifically, the molecular basis of these disorders is increasingly being understood, therapeutic genes are available, and alternative therapies are often lacking. Most recently, the field of gene therapy has enjoyed the realization of the first incontrovertible evidence of clinical benefit, for hemophilia and cardiovascular disease, in its first 15 years of human application.2 This recent recognition of the potential power of gene therapy, and the current lack of realizing such ends for neoplastic disease, has led to a reassessment of the field. Such a critical analysis is a necessary step in defining the means to progress the technology toward achieving the potential benefits of gene therapy for cancer.

AB - The 'First International Symposium on Genetic Anticancer Agents,' which took place in Amsterdam on March 8-9, 2000, served as a forum to review the results of preclinical and clinical gene therapy studies for cancer endeavored to date. Despite the fact that gene therapy was initially conceptualized as an approach for inherited genetic disease, it is currently finding its widest employ for treating neoplastic disorders. In this regard, more than 70% of patients treated to date in human clinical gene therapy protocols have been in the context of anticancer regimens.1 Of note, the application of gene therapy for cancer has proceeded from the same rational basis as was originally conceptualized for inherited genetic disorders. Specifically, the molecular basis of these disorders is increasingly being understood, therapeutic genes are available, and alternative therapies are often lacking. Most recently, the field of gene therapy has enjoyed the realization of the first incontrovertible evidence of clinical benefit, for hemophilia and cardiovascular disease, in its first 15 years of human application.2 This recent recognition of the potential power of gene therapy, and the current lack of realizing such ends for neoplastic disease, has led to a reassessment of the field. Such a critical analysis is a necessary step in defining the means to progress the technology toward achieving the potential benefits of gene therapy for cancer.

KW - Clinical trials

KW - Gene therapy

KW - Preclinical research

KW - Replication

KW - Targeting

KW - Vectors

UR - http://www.scopus.com/inward/record.url?scp=0033845884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033845884&partnerID=8YFLogxK

M3 - Article

C2 - 10975681

AN - SCOPUS:0033845884

VL - 7

SP - 1197

EP - 1199

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 8

ER -